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Abstract
Purpose of Review Given the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with
rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients.
Recent Findings Significant advances have been made in the management of rheumatic diseases in the past two decades. The
introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to
better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and
adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment
options.
Summary Since 2012, Janus kinase (JAK) inhibitors (JAKinibs), a novel group of oral small molecule inhibitors, have demon-
strated their efficacy in several forms of adult inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis
(PsA). There are hopes that these successes will be transferable to the paediatric population. In the following review, we discuss
the development and progress of JAKinibs in this regard.
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Introduction
The treatment of paediatric rheumatic diseases has evolved
markedly over the past two decades. The development of bio-
logical disease-modifying anti-rheumatic drugs (bDMARDs)
has provided a significant armamentarium to rheumatologists,
improving clinical outcomes for patients. Unfortunately, a
subset of patients either remain unresponsive to these agents,
experience partial or loss of efficacy, or have adverse events
during treatment necessitating discontinuation. Hence, there is
an unmet need for such refractory patients. JAK inhibitors
(JAKinibs) are small molecule inhibitors of the Janus Kinase
family of receptors. JAK-mediated pathways are known to be
implicated in the pathogenesis of rheumatoid arthritis (RA),
psoriatic arthritis (PsA), inflammatory bowel disease (IBD),
as well as several other immune-mediated inflammatory dis-
eases (IMIDs) [1, 2]. Crucially, these small molecule inhibi-
tors provide a novel mechanism of action in treating these
conditions by affecting intracellular signalling pathways.
Substantial evidence for the use of JAKinibs has been dem-
onstrated in multiple successful clinical trials in adults with
RA and PsA. [3–5].
Juvenile idiopathic arthritis (JIA) is the most common pae-
diatric rheumatic disease and is associated with significant
morbidity [6]. Treatment of polyarticular and systemic JIA
entails the use of non-steroidal anti-inflammatory drugs
(NSAIDs) and convent ional synthet ic DMARDs
(csDMARDs) [7]. Lately, bDMARDs targeting cytokines im-
plicated in pro-inflammatory pathways, such as interleukin-1
and -6 (IL-1 and IL-6), and tumour necrosis factor-α (TNF-α),
amongst others, have markedly advanced the treatment of
otherwise recalcitrant disease. JAKinibs have now been ap-
proved for use in adults with RA and PsA, and phase 3 studies
are underway to establish the role and efficacy of these mol-
ecules in the treatment of JIA. There is also interest into
whether they may provide therapeutic potential in a group of
autoinflammatory conditions of the innate immune system
termed ‘type 1 interferonopathies’. We discuss below the cur-
rent knowledge base and progress in establishing the role for
JAKinibs within paediatric rheumatology.
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JAK Structure and Signalling
There are four known JAKs (JAK 1, 2, 3 and TYK2), which
are members of the tyrosine kinase (TYK) family of protein
kinases [8]. Every JAK is composed of 4 structural domains,
within which there exist seven homologous regions (JH1-7).
JH1 (kinase domain) is the primary catalytic phosphotransfer-
ase, whereby ATP is bound, both autophosphorylating the
JAK complex and phosphorylating signal transducers and ac-
tivators of transcription (STATs) [9]. JAKinibs effect their
function via competitive inhibition of the ATP binding site
on JH1 [8]. Notably, JAK family proteins exhibit a high de-
gree of structural homology, the most pronounced of which is
seen in the JH1 subunit. There is furthermore significant ho-
mology between JAKs and other tyrosine kinases [8].
Difficulties have therefore arisen in developing a selective
kinase inhibitor, with cross-JAK side-effects being present
amongst especially first generation JAKinibs (Fig. 1).
JAK-STAT signalling is implicated in several cytokine
pathways: type I/II cytokines bind to their receptors and acti-
vate JAKs, which phosphorylate STATs initiating downstream
signalling cascades. Each cytokine receptor is composed of
several intracellular subunits; each subunit in turn associates
with a JAK. Hence, varying JAK subtypes become paired
when associated with distinct receptors, for example common
gamma chain (γc) receptor associates with JAK3 and JAK1
(Fig. 1) [10]. Receptor subunits have varying degrees of spec-
ificity: some associate exclusively with specific JAKs; others
possess less specificity. This has potential implications for
drug development, treatment considerations and side-effect
profiles.
Disease Entities—Clinical and Molecular
Aspects
Juvenile Idiopathic Arthritis (JIA)
Juvenile idiopathic arthritis (JIA) is a terminology used for a
broad range of immune-mediated articular disorders affecting
children less than 16 years of age. Six phenotypic forms of JIA
are recognised [6], which are subtyped based on clinical fea-
tures, genetics, serology and systemic involvement. Notably,
approximately 20% of children fail to meet criteria for any of
the specific subtypes and are termed ‘undifferentiated’ [6].
The common responses elicited to biologic therapeutic inter-
ventions between adult and juvenile disease point to shared
pathogenetic pathways, especially in the context of inflamma-
tory synovitis. For example, RhF positive polyarticular JIA
closely resembles adult RA in its disease manifestations and
natural disease trajectory, though data elucidating similarities
at a molecular level in synovium are limited. A study exam-
ining genotypic risk loci was performed by Prahalad et al in
155 children with RhF positive JIA and 684 healthy controls
[11•]. They established an increased risk in children with var-
iants in genes encoding PTPN22, STAT4 and TNFAIP3 in a
similar magnitude and direction as previously observed in
adults with RA. Additionally, they demonstrated significant
association between this subtype of JIA and HLA-DRB1 al-
leles previously outlined as conferring increased risk in RA
patients. On the other hand, gene expression profiles from
PBMCs obtained from children with various subtypes of JIA
have shown divergence between sJIA and polyarticular dis-
ease [12]. sJIA and its adult form, adult-onset Still's disease
(AOSD), share common pathophysiological mechanisms:
they have been shown to associate with raised serum levels
of IL-1, IL-6, and IL-18 [13, 14]. Interestingly, in both sJIA
and AOSD, increased serum levels of IL-18 have been ob-
served to correlate with disease activity and with the risk of
developing the potentially life-threateningmacrophage activa-
tion syndrome (MAS), a complication notable for its
haemophagocytic activity [13, 15].
Taken together, it is reasonable to assume that there will be
benefit of therapeutics established in adult inflammatory ar-
thritis in the wider juvenile inflammatory syndromes.
Interferonopathies
Type I interferons are fundamental to innate immunity. Toll-
like receptors 3, 7 and 9 (TLR3, 7 and 9) are pattern
Fig. 1 Specific Janus Kinases associate with different receptors [8]. Janus
kinases (JAKs) consist of four subtypes: JAK1, 2, 3 and TYK2. Different
receptors signal exclusively via specific JAK subtypes. Receptor subunits
have varying affinity for these separate JAKs. First generation JAK
inhibitors (JAKinibs) have a side effect profile influenced by their
cross-JAK effects, e.g. haematological sequelae due to blockade of
JAK2. EPO: erythropoietin; G-CSF: granulocyte colony-stimulating
factor; GH: growth hormone; GM-CSF: granulocyte-macrophage
colony-stimulating factor; IL: interleukin; TPO: thrombopoietin; TYK:
tyrosine kinase
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recognition receptors (PRRs) expressed onmacrophages, den-
dritic cells and B cells [16] and in turn drive IFN expression
and thereby downstream consequences of IFN effector biolo-
gy [17]. Transcriptional activation of relevant loci and in-
creased expression of IFN is governed by distinct pathways
downstream of DNA and RNA sensors (Fig. 2). RNA sensors
include retinoic acid-inducible-I (RIG-I)-like helicases, RIG-I
and melanoma differentiation-associated protein 5 (MDA5),
which signal via mitochondrial antiviral signalling (MAVS)
adaptor protein [17], stimulating signalling pathways involved
in activation of nuclear factor-κB (NF-κB) and interferon-
regulatory factors (IRFs) IRF3 and IRF7, which lead to tran-
scription and subsequent production of IFN-α, along with
other pro-inflammatory cytokines [17]. DNA sensing is chief-
ly performed by cyclic GMP-AMP synthase (cGAS), which,
following single stranded DNA (ssDNA) or double stranded
DNA (dsDNA) binding, in turn enzymatically produces cyclic
GMP-AMP (cGAMP) [19]. cGAMP thereafter signals
through stimulator of interferon genes (STING), similarly ac-
tivating IRF3 and producing type 1 IFN. Upon release of IFN
from the cell, an autocrine and paracrine loop is established,
whereby type 1 IFNs (IFN-α and IFN-β) bind to the
interferon-α receptor (IFNAR), associated intracellularly with
a heterodimer of JAK1 and TYK2. Consequent STAT1/2 re-
cruitment and phosphorylation triggers increased transcription
of IFNB and ISGs [19]. These defence mechanisms confer
antiviral properties to the infected cell and surrounding milieu.
This heightened pro-inflammatory state disturbs routine cell
functions, such as metabolism, and prompts recruitment and
activation of adaptive effector cells (Fig. 2).
It is well established that recurrent inflammatory fea-
tures presenting in juvenile patients at an early age may
represent primary genetic disorders of innate inflammatory
pathways, such as Familial Mediterranean Fever (FMF), or
cryopyrin-associated periodic syndrome (CAPS). Type 1
interferonopathies represent a heterogeneous group of dis-
orders, both genetically and phenotypically, with abnormal-
ities in discrete stages of nucleic acid metabolism or in
cytoplasmic nucleic acid sensors, concluding in a final
common pathway marked by aberrant overproduction of
type 1 IFNs [20]. A broad range of clinical manifestations
can occur in these patients, largely characterised by onset
of autoinflammatory and autoimmune features early in life
(Table 1). These disorders are unified by detection in pe-
ripheral blood of a marked elevation in type 1 interferon
gene signature (IGS). (Table 1)
Pharmacological management of these conditions has
proven to be challenging. Patients are currently treated with
high doses of glucocorticoids orally or intravenous, and intra-
venous immunoglobulins may be considered. Patients may
struggle to wean glucocorticoids due to recurrence of symp-
toms. Avariety of steroid-sparing agents have been employed
with limited or no clinical success, including methotrexate,
mycophenolate mofetil, azathioprine, hydroxychloroquine,
as well as biologic agents antagonising IL-1, TNF or IL-6
[18••, 25, 34]. It has been considered that agents targeting
specific components of the IFN signalling pathways may pro-
vide more positive clinical results. Given the criticality of the
JAK/STAT pathway in the promulgation of the signal from the
IFNAR, JAKs provide high biological plausibility as effica-
cious targets in these relatively treatment resistant conditions.
Our current accumulated experience of use of specific
JAKinibs in this patient cohort is discussed in more detail
below.
Fig. 2 Type 1 Interferon signalling and production [18••]. The innate
immune system has developed sensing mechanisms against nucleic acid
components as a defence against viral infections. Sensing of
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) is controlled
by separate signalling pathways with the common final result of increased
production of type 1 interferon (IFN). An autocrine feedback loop occurs
via the IFN-α receptor (IFNAR), further contributing to upregulation of
IFN secretion. Mutations in genes regulating key sensing mechanisms,
such as TREX1, SAMHD1 and STING, can produce aberrantly high type
1 IFN levels, a defining characteristic of interferonopathies. cGAMP:
cyclic GMP-AMP; cGAS: cyclic GMP-AMP synthase; IRF: interferon-
regulatory factor; JAK: janus kinase; IFN: interferon; MAVS:
mitochondrial anti-viral signalling; MDA5: melanoma differentiation-
associated protein 5; RIG-I: retinoic acid-inducible-I; STING:
stimulator of interferon genes
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Tofacitinib
Tofacitinib is a first-generation JAKinib and was the first
JAKinib designed to specifically treat IMIDs [10]. This
compound inhibits JAK1 and JAK3 primarily; JAK2 ac-
tivity is inhibited to a lesser extent; and TYK2 activity is
negligible [8]. Notably, metabolism of tofacitinib is
primarily hepatic via the cytochrome P450 (CYP) system
[9]. (Table 2)
Tofacitinib at 5 and 10mg orally twice daily has been in-
vestigated extensively in adults in a series of clinical trials,
including six phase III trials involving more than 6000 pa-
tients with RA [36, 37]. Efficacy in reducing disease activity,
as measured by American College of Rheumatology 20%,
Table 1 Type 1 Interferonopathies.Mutated gene, pattern of inheritance
and manifestations. Adapted from Table 1 in Volpi S, Picco P, Caorsi R,
Candotti F, Gattorno M. Type I interferonopathies in pediatric
rheumatology. Pediatric Rheumatology. Pediatric Rheumatology; 2017
Sep 1;:1–12, under the terms of the Creative Commons Attribution 4.0
International License
Disease Gene Inheritance Manifestations
Aicardi-Goutière Syndrome
(AGS) 1 [21, 22•]
TREX-1 AR and
AD
Progressive encephalopathy, basal ganglia calcifications, lymphocytosis,
raised IFN-α in CSF (Classical AGS)
AGS2 [22•] RNASEH2B AR Clinical features of AGS
AGS3 [22•] RNASEH2C Clinical features of AGS
AGS4 [22•] RNASEH2A AGS with dysmorphic features
AGS5 [22•] SAMHD1 AR Mild AGS, mouth ulcers, deforming arthropathy, cerebral vasculopathy with
early onset stroke
AGS6 [22•] ADAR AR and
AD
Classical AGS, bilateral striatal necrosis
AGS7 [22•] IFIH1 AD Classical or mild AGS, though may be asymptomatic
Retinal vasculopathy with
cerebral leukodystrophy
(RVCL) [23]
TREX-1 AD Retinopathy and cerebrovascular disease, leukodystrophy, dementia,
migraines, glomerulopathy
Spondyloenchondrodysplasia
(SPENCD) [24]
ACP5 AR Spondyloenchondrodysplasia, possible combined immunodeficiency, arthritis,
thrombocytopenia, short stature
STING associated vasculopathy
with
onset in infancy (SAVI) [25]
TMEM173 AD Cutaneous vasculopathy especially acral involvement, interstitial lung disease,
fever, arthralgia
USP18 deficiency [26] USP18 AR Cerebral calcification and haemorrhage, hepatomegaly, thrombocytopenia
ISG15 deficiency [18••] ISG15 AR Increased susceptibility to mycobacterial infections, basal ganglia
calcification, seizures
Singleton-Merten Syndrome
(SMS) [27, 28]
IFIH1, DDX58 AD Cardiovascular sequelae, aortic calcification, dental and skeletal abnormalities,
psoriasiform cutaneous lesions
Chronic atypical neutrophilic
dermatosis
with lipodystrophy and
elevated temperature
(CANDLE) [29]
PSMA3, PSMB4,
PSMB8, PSMB9,
POMP
AD Panniculitis, lipodystrophy, joint contractures, basal ganglia calcification,
fever, arthritis, myositis, dyslipidaemia and metabolic syndrome, aseptic
lymphocytic meningitis
Trichohepatoenteric syndrome
(THES) [30]
SKIV2L AR Intractable diarrhoea, woolly hair, intrauterine foetal growth restriction, facial
dysmorphism and short stature, immunodeficiency
X-linked reticulate pigmentary
disorder (XLPDR)[31]
POLA1 XR Hyperpigmented skin lesions; GI disease including gastroenteritis, colitis;
failure to thrive
DNase II deficiency [32] DNASE2 AR Cytopenias, hepatosplenomegaly, fever, non-erosive deforming arthropathy,
cutaneous vasculitic lesions, membranoproliferative glomerulonephritis
Familial chilblain lupus [33] TREX1, SAMHD1,
TMEM173
AD Chilblain lesions, arthralgia, lymphopenia
ADAR1 adenosine deaminase acting on RNA 1, ACP5 acid phosphastase 5, tartrate resistant, AGSAicardi-Goutière syndrome, AD autosomal dominant,
AR autosomal recessive, CANDLE chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, CSF cerebrospinal fluid,
DDX58 DEAD box protein 58, IFIH1 IFN-induced helicase C domain-containing protein 1, ISG15 interferon-stimulated gene 15, POLA1 DNA
polymerase alpha 1, PSMA proteosome subunit alpha type, PSMB proteosome subunit beta type, RNASEH2 ribonuclease H2, RVCL Retinal vasculop-
athy with cerebral leukodystrophy, SAMHD1 deoxynucleoside triphosphohydrolase SAM domain and HD domain 1, SPENCD
spondyloenchondrodysplasia, SAVI STING associated vasculopathy with onset in infancy, PRAAS proteosome-associated autoinflammatory syndrome,
SMS Singleton-Merten Syndrome, THES Trichohepatoenteric syndrome, TMEM173 Transmembrane protein 173, TREX1DNA 3’ – repair exonuclease
1, USP18 ubiquitin-specific peptidase 18, XLPDR X-linked reticulate pigmentary disorder, XR X-linked recessive
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50%, and 70% response criteria (ACR 20, 50, 70), has been
demonstrated in DMARD-naïve, csDMARD inadequate re-
sponders (csDMARD-IR), and bDMARD-IR cohorts. To
date, only two RCTs have assessed tofacitinib in PsA, and
have similarly illustrated benefit in patients with inadequate
response to csDMARDs and bDMARDs (discussed below).
In the ORAL Start study, tofacitinib has shown superiority
to methotrexate (MTX) in clinical, functional, and radiograph-
ic outcomes in DMARD-naïve patients [38]. Non-inferiority
to adalimumab, a TNFα-inhibitor, has been demonstrated in
RA patients who are inadequate responders to MTX. ORAL
Standard and Strategy present supportive data that tofacitinib
in combination with MTX performs as well as adalimumab in
combination with MTX in achieving ACR20 and ACR50
responses at 6 months [3, 4, 39]. Additional data from these
trials highlighted that clinically significant improvements in
disease activity measures were achieved earlier than with con-
ventional biological agents, and that responses were sustained
over a 12-month period. Patients who were inadequate re-
sponders to bDMARDs demonstrated significant improve-
ments in ACR20 and HAQ versus placebo. Based on these
data, tofacitinib has been approved by the US Food and Drug
Administration (US FDA) and the UK-based National
Institute for Health and Care Excellence (NICE) for the treat-
ment of moderate to severe RA.
Tofacitinib has also shown efficacy in adult patients with
PsA. OPAL Broaden demonstrated superiority of tofacitinib
doses of 5mg or 10mg compared to placebo in csDMARD-IR
patients, with significant improvements in ACR20 and HAQ-
DI scores at 3 months [40]. OPAL Beyond provided evidence
of clinical benefit from tofacitinib in patients with inadequate
response to 1 or more anti-TNF bDMARDs. ACR20 and
HAQ-DI values improved significantly compared to placebo
at 3 months [41].
Data relating to the use of tofacitinib in JIA are more limit-
ed. Preliminary studies have sought to establish the safety and
pharmacokinetics (PK) of tofacitinib in the JIA population. A
phase 1, open-label, multicentre study by the Paediatric
Rheumatology International Organisation (PRINTO) and
the Paediatric Rheumatology Collaborative Study Group
(PRCSG) enrolled twenty-six patients aged 2–17 years [42].
All patients had polyarticular JIA, with rheumatoid factor neg-
ative polyarthritis variant being most common (84.6% of all
patients in the study). Study participants entered one of three
cohorts, based on age: cohort 1, aged 12 to < 18 years; cohort
2, aged 6 to < 12 years; cohort 3, aged 2 to < 6 years. Median
doses of tofacitinib were 5.0 mg BID, 2.5 mg BID, and 3.0 mg
BID respectively, based on body weight. The unexpected in-
crease in median dose of drug in cohort 3 resulted from an
interim PK analysis of cohorts 1 and 2 and consequent amend-
ment to dosing scheme to cohort 3. Accordingly, geometric
mean AUC at steady state (AUCtau) in cohort 2 (118.8 ng h/
ml) was lower than cohort 1 (156.6 ng h/ml), while cohort 3
showed a higher AUCtau value (142.5 ng h/ml). Cmax (ng/ml)
was 47.0, 41.7, and 66.2 in cohorts 1, 2 and 3, respectively.
Ctrough, Cmin and t1/2 were comparable in cohorts 2 and 3, but
higher in cohort 1. Tofacitinib was well tolerated and had no
serious adverse events (SAEs) or discontinuations due to ad-
verse events (AEs). A grape-flavoured solution was used in
younger patients and those with lower weight, and this formu-
lation was acceptable.
Further to these PK data, efficacy and safety of tofacitinib 1-
5mg BID is being determined in a currently-recruiting Phase 3,
randomised, double-blind placebo-controlled study of
polyarticular JIA patients (A3921104; Clinicaltrials.gov:
NCT02592434). A long-term, open-label phase 2/3 extension
study is ongoing for those JIA patients who have
previously enrolled in qualifying/index studies of tofacitinib,
including the phase 1 study detailed above (A3921165;
Clinicaltrials.gov: NCT01500551). In addition to use within
the polyarticular JIA cohort, a randomised withdrawal double-
blind placebo-controlled study is currently recruiting to eval-
uate the safety, efficacy and pharmacokinetics of tofacitinib
in patients with sJIA (A3921165; ClinicalTrials.gov:
NCT03000439).
Tofacitinib has been reported to provide benefit in case
reports of individuals with interferonopathies. König et al
describe a family of Greek descent with five members affect-
ed by familial chilblain lupus aged between 12 and 86 years
[43, 44]. Original age of onset of symptoms was between 2
months and 12 years of age. Symptoms included cold-
induced digital vasculopathy of the fingers, toes, nose,
cheeks and ears or with indurated violaceous patches on
the thighs. Necrotic ulceration occurred in some cases. No
haematological abnormalities were detected, but low titre
ANAs were found in 4 out of 5 patients, and one had a high
titre of anti-C1q antibodies. Whole exome sequencing iden-
tified a novel heterozygous mutation in STING (c.497G>A;
p.Gly166Glu, p.G166E). Two of these family members were
treated with oral tofacitinib 5 mg twice daily for 17 days. At
day 14, ISG in peripheral blood was found to have signifi-
cantly reduced and patients reported a reduction in digital
discomfort.
Table 2 Enzyme assay values for half maximal inhibitory
concentration (IC50) for current JAKinibs
Enzyme assay IC50 (nM)
Compound JAK1 JAK2 JAK3 TYK2
Tofacitinib [8] 15.1 77.4 55.0 489
Baricitinib [8] 4.0 6.6 787.0 61.0
Ruxolitinib [8] 6.4 8.8 487.0 30.1
Filgotinib [35] 363 2400 > 10,000 2600
Peficitinib [36] 3.9 5.0 0.71 4.8
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Separately, a team of Korean clinicians report the use of
tofacitinib in a 9-year-old boy with SAVI [45]. From 6–
12 months of age, the child exhibited increased infection fre-
quency and features of vasculopathy (skin telangiectasia). At
age 5, he suffered an unprovoked cerebral infarction. At age 8,
he developed interstitial lung disease (computed tomography
evidence of obliterative bronchiolitis) requiring supplemental
oxygen therapy, and further cerebral infarction accompanied
by subarachnoid haemorrhages. Whole-exome sequencing re-
vealed 2 de novo variants in TMEM173. Primary cultured
fibroblasts taken from the affected patient exhibited signifi-
cantly raised IFN-βmRNA levels before and after stimulation
with cGAMP. Treatment with oral tofacitinib 5mg BID led to
improvement in telangiectatic skin lesions, but not of the pa-
tient’s respiratory function, possibly due to established dam-
age caused by inflammatory insult.
Baricitinib
Baricitinib is a first-generation selective JAK 1 and 2 inhibi-
tor, which has similarly proven efficacy in RA in a variety of
clinical scenarios. Baricitinib at doses of 2 mg and 4 mg once
daily by oral preparation have undergone evaluation in multi-
ple phase III studies, demonstrating safety and efficacy in
achieving clinically meaning improvements in disease activi-
ty, radiographic measures and patient-reported outcomes [46,
47]. In the RA-BEACON study, baricitinib exhibited efficacy
in bDMARD-IR patients [35, 48]. Interestingly, baricitinib has
also been shown to possess superiority to adalimumab in a
cohort ofMTX-IR patients, achieving a new landmark in drug
development for RA. Such data have led to the approval of
baricitinib for RA in more than 40 countries, including by the
European Medicines Agency (EMA) and NICE; however,
concerns regarding the increased risk of venous thromboem-
bolism led the FDA to reject the approval of baricitinib at that
time, instead requesting further clinical safety data. A resub-
mission has been considered by the FDA Arthritis Advisory
Committee, who have recommended only the lower 2mg once
daily dosing.
There exist no data on baricitinib use in JIA, and there are
no clinical trials at present evaluating its use in this context.
Instead, a current open-label compassionate use study
(ClinicalTrials.gov: NCT01724580) is employing baricitinib
for treatment of autoinflammatory diseases, including
interferonopathies. Sanchez et al report on 18 patients treated
with baricitinib within this program [49]. Ten patients had
genetically confirmed CANDLE syndrome, four with geneti-
cally confirmed SAVI, and four with other IFNopathies. Mean
age at enrolment was 12.5 with 78% of patients having been
on glucocorticoid (GC) therapy for an average 5.7 years
(range 1–17 years) prior to enrolment. All patients had been
inadequate responders to previous csDMARDs and
bDMARDs. Mean duration of treatment was 3.0 years (1.5–
4.9), and median daily symptom scores improved significant-
ly from 1.3 to 0.25 (p < 0.0001). Fourteen patients were re-
ceiving GC at baseline; of this cohort, daily GC doses de-
creased from 0.44 to 0.11 mg/day (p < 0.001). Five of 10
(50%) CANDLE patients interestingly achieved sustained
clinical remission. In this sub-group of patients, with the most
marked clinical response, the 25-gene IFN score normalised
completely. The four SAVI patients still experienced flares of
vasculitis, though reduced in frequency and intensity, and no
patients suffered further digital amputation during treatment.
No SAVI patients achieved normalisation of the 25-gene IFN
score. Three patients discontinued drug, two with genetically
undefined disease due to primary inefficacy, and a CANDLE
patient due to infectious complication (BK viraemia). Serious
adverse events (SAEs) were frequent, with 83% of patients
experiencing at least one SAE. In most cases, these resolved
without treatment interruption. Infectious sequelae were con-
sistent with established data in adults: upper respiratory tract
infections were most common, and herpes zoster was ob-
served in two patients. Notably, transient cytopenias was ob-
served to accompany infections. BK viraemia was detected in
one patient leading to acute renal injury and treatment discon-
tinuation. This has not been observed in adult rheumatology
patients, though has been observed in trials evaluating the use
of tofacitinib in preventing renal transplant rejection [50].
Hence, high clinical suspicion should be exercised in patients
with new or worsening renal dysfunction upon commence-
ment of JAKinib therapy.
Ruxolitinib
Ruxolitinib is a selective oral JAK 1/2 inhibitor with proven
efficacy reduce symptoms and splenomegaly in adult myelo-
fibrosis. Frémond et al describe 3 children with SAVI treated
with ruxolitinib [51]. The patients were aged 5 to 12 years and
had genetically proven SAVI: gain-of-function TMEM173
mutations in the context of clinical features consistent with
SAVI (vasculopathy, interstitial pulmonary disease, systemic
inflammation). Treatment with ruxolitinib led to favourable
results in patient-reported well-being, reduction in febrile ep-
isodes and in skin lesions, along with improvement in lung
function. Similar to the baricitinib study described above, in-
complete IFN IGS normalisation was observed in these pa-
tients. The authors report no increase in incidence of infection
in any of the 3 children.
Adverse effects associated with JAKinib use
Immune modulation via JAK/STAT signalling carries with it
side effects commensurate with blocking this pathway.
Tofacitinib has been the most widely used and studied agent,
but accumulating data on the other agents suggest similar
profiles.
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As with other immunosuppressive agents, it can be expect-
ed that JAKinibs carry an increased risk of infection. The large
RCTs in adult RA patients reported infections commonly as
adverse events (AEs) [52]. The most frequent sites of infection
were upper respiratory tract, urinary, and viral gastroenteritis.
The majority of infections did not necessitate treatment dis-
continuation. More severe and opportunistic infections were
observed, such as tuberculosis (TB), fungal and Pneumocystis
jirovecii pneumonia [data indicate that the overall infective
risk does not seem to be significantly increased compared to
established biologic agents [53, 54]]. One notable difference
to other biologics is the increased risk of varicella zoster in-
fection (VZV). There exist hypotheses about the mechanism
behind this, such as effects on NK cell function or IFN pro-
duction, but these have not yet been fully elucidated. In Asian
populations, chemokine functional polymorphisms have also
been implicated. BK viraemia has also been detailed above.
Given the effects of JAKinibs on IL-6 signalling, lipid pro-
file abnormalities are similarly to be expected, as is seen com-
monly with the IL-6-receptor (IL-6R) antagonist tocilizumab.
RA patients have an increased cardiovascular morbidity and
mortality when compared with age and sex matched healthy
controls, despite active RA being associated with reduced
levels of low-density lipoprotein cholesterol and total choles-
terol [55]. There exist some data to suggest that tofacitinib
treatment reduces cholesterol ester catabolism, hence increas-
ing cholesterol levels towards those of healthy controls [56].
Reassuringly, clinical trials and long-term extension data have
not borne out an increased risk of cardiovascular disease with
any of the JAKinib family.
JAK2 mediates signalling of cytokines involved in haema-
tological cellular proliferation and survival, such as erythro-
poietin and G-CSF; hence, patients are at risk of developing
cytopenias, including anaemia and leukopenia. Reassuringly,
trial data suggest that these usually did not require treatment
discontinuation. The development of newer generation
JAKinibs seeks to mitigate this potentially undesirable effect.
Other potential adverse effects reported in trials include tran-
sient reductions in renal function, mild increases in serum
transaminases [57], and increased risk of gastrointestinal per-
foration similar to tocilizumab [54].
Conclusion
Over the last two decades, improved treatments for rheumatic
diseases have offered great promise to patients and their fam-
ilies. Patients with rheumatic diseases within the adult popu-
lation have benefited from several large successful phase III
trials supporting the introduction of multiple biologic and
targeted synthetic DMARDs. The scale of research in this
field in relation to the paediatric population is significantly
more limited. The advent of oral JAKinib therapies heralds a
potentially exciting era in paediatric rheumatology—their role
in JIA is especially anticipated for broader clinical practice,
whilst rarer conditions will presumably also benefit.
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